VEGFA and ovarian carcinoma: These antitumoral effects are possibly associated with changes in the secretion profile of ovarian cancer cells, especially higher production of anti-tumor cytokines (IL-1ra, IL-2Ra, IL-12-p40, IL-12-p70, and IFN-γ) and decreased level of cancer-promoting cytokines (IL-6, IL-8, GRO-alpha, angiopoetin-2, and VEGF) after HATMSC2-MVs treatment [17].